A Multi-center, Double-blind, Placebo-controlled Phase 4 Study in Patients With Pulmonary Arterial Hypertension to Assess the Effect of Selexipag on Daily Life Physical Activity and Patient's Self-reported Symptoms and Their Impacts
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Oct 2017
At a glance
- Drugs Selexipag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms TRACE
- Sponsors Actelion Pharmaceuticals
- 03 Oct 2017 Planned initiation date changed from 30 Sep 2017 to 31 Oct 2017.
- 08 Sep 2017 Planned End Date changed from 29 Mar 2019 to 28 Dec 2019.
- 08 Sep 2017 Planned primary completion date changed from 29 Mar 2019 to 28 Dec 2019.